LANREOTIDE ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Lanreotide Acetate patents expire, and when can generic versions of Lanreotide Acetate launch?
Lanreotide Acetate is a drug marketed by Invagen Pharms and is included in two NDAs.
The generic ingredient in LANREOTIDE ACETATE is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lanreotide Acetate
A generic version of LANREOTIDE ACETATE was approved as lanreotide acetate by INVAGEN PHARMS on December 17th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LANREOTIDE ACETATE?
- What are the global sales for LANREOTIDE ACETATE?
- What is Average Wholesale Price for LANREOTIDE ACETATE?
Summary for LANREOTIDE ACETATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,430 |
| What excipients (inactive ingredients) are in LANREOTIDE ACETATE? | LANREOTIDE ACETATE excipients list |
| DailyMed Link: | LANREOTIDE ACETATE at DailyMed |
Recent Clinical Trials for LANREOTIDE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Debiopharm International SA | Phase 1 |
| Ipsen | Phase 1/Phase 2 |
| Ipsen | Phase 3 |
Pharmacology for LANREOTIDE ACETATE
| Drug Class | Somatostatin Analog |
| Mechanism of Action | Somatostatin Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for LANREOTIDE ACETATE
US Patents and Regulatory Information for LANREOTIDE ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 217193-001 | May 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-002 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 217193-002 | May 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-003 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
